ANGO's NanoKnife growth, strong Med Tech momentum and solid Q3 results support holding the stock despite tariff and inflation pressures.

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a ...

Shares of AngioDynamics (ANGO) have gained 0.1% over the past four weeks to close the last trading session at $10.06, but there could still be a solid upside left in the stock if short-term price ...

Tuesday, AngioDynamics Inc (NASDAQ: ANGO) reported a fourth-quarter 2024 adjusted EPS loss of $0.05, compared to the consensus loss of $0.16. Fourth-quarter sales totaled $70.98 million, beating the ...

AngioDynamics' FDA IDE approval for RELIEF advances NanoKnife IRE study as a potential minimally invasive BPH treatment.

AngioDynamics Inc (NASDAQ: ANGO) has reported a second-quarter (Q2) FY24 adjusted EPS loss of $(0.05), compared to the consensus of $(0.07) and EPS income of 1 cent reported a year ago. Q2 sales ...

AngioDynamics prepares to report fiscal fourth-quarter results as attention turns to revenue trends, device demand, valuation, and business progress.

A downtrend has been apparent in AngioDynamics (ANGO) lately with too much selling pressure. The stock has declined 15.9% over the past four weeks. However, given the fact that it is now in oversold ...

A downtrend has been apparent in AngioDynamics (ANGO) lately with too much selling pressure. The stock has declined 5.8% over the past four weeks. However, given the fact that it is now in oversold ...